Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free AGPU Stock Alerts

Predictive Oncology (AGPU) Competitors

Predictive Oncology logo
$7.11 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$7.22 +0.11 (+1.50%)
As of 09:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AGPU vs. TMCI, SGHT, PROF, OBIO, and TLSI

Should you buy Predictive Oncology stock or one of its competitors? MarketBeat compares Predictive Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Predictive Oncology include Treace Medical Concepts (TMCI), Sight Sciences (SGHT), Profound Medical (PROF), Orchestra BioMed (OBIO), and TriSalus Life Sciences (TLSI). These companies are all part of the "medical equipment" industry.

How does Predictive Oncology compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Treace Medical Concepts currently has a consensus price target of $4.77, suggesting a potential upside of 17.49%. Given Treace Medical Concepts' stronger consensus rating and higher possible upside, analysts clearly believe Treace Medical Concepts is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Treace Medical Concepts
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Treace Medical Concepts has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 3.47, suggesting that its share price is 247% more volatile than the broader market.

Treace Medical Concepts has higher revenue and earnings than Predictive Oncology. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Treace Medical Concepts$212.69M1.24-$59M-$0.97N/A
Predictive Oncology$120K641.09-$233.10M-$8.18N/A

Treace Medical Concepts has a net margin of -29.44% compared to Predictive Oncology's net margin of -470,383.31%. Treace Medical Concepts' return on equity of -67.04% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Treace Medical Concepts-29.44% -67.04% -30.28%
Predictive Oncology -470,383.31%-7,363.67%-626.32%

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Treace Medical Concepts had 3 more articles in the media than Predictive Oncology. MarketBeat recorded 5 mentions for Treace Medical Concepts and 2 mentions for Predictive Oncology. Treace Medical Concepts' average media sentiment score of 1.56 beat Predictive Oncology's score of 0.93 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Treace Medical Concepts
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Predictive Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Treace Medical Concepts beats Predictive Oncology on 13 of the 16 factors compared between the two stocks.

How does Predictive Oncology compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Predictive Oncology had 1 more articles in the media than Sight Sciences. MarketBeat recorded 2 mentions for Predictive Oncology and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.87 beat Predictive Oncology's score of 0.93 indicating that Sight Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Sight Sciences Very Positive
Predictive Oncology Positive

Sight Sciences has a beta of 2.41, meaning that its stock price is 141% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 3.47, meaning that its stock price is 247% more volatile than the broader market.

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 30.9% of Sight Sciences shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sight Sciences presently has a consensus target price of $8.14, suggesting a potential upside of 58.75%. Given Sight Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Sight Sciences is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sight Sciences
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Sight Sciences has higher revenue and earnings than Predictive Oncology. Sight Sciences is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sight Sciences$79.55M3.51-$38.43M-$0.71N/A
Predictive Oncology$120K641.09-$233.10M-$8.18N/A

Sight Sciences has a net margin of -46.83% compared to Predictive Oncology's net margin of -470,383.31%. Sight Sciences' return on equity of -52.34% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Sight Sciences-46.83% -52.34% -28.49%
Predictive Oncology -470,383.31%-7,363.67%-626.32%

Summary

Sight Sciences beats Predictive Oncology on 12 of the 16 factors compared between the two stocks.

How does Predictive Oncology compare to Profound Medical?

Predictive Oncology (NASDAQ:AGPU) and Profound Medical (NASDAQ:PROF) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Profound Medical has a net margin of -206.76% compared to Predictive Oncology's net margin of -470,383.31%. Profound Medical's return on equity of -78.88% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Predictive Oncology-470,383.31% -7,363.67% -626.32%
Profound Medical -206.76%-78.88%-64.06%

Predictive Oncology has a beta of 3.47, indicating that its stock price is 247% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

In the previous week, Predictive Oncology had 1 more articles in the media than Profound Medical. MarketBeat recorded 2 mentions for Predictive Oncology and 1 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.89 beat Predictive Oncology's score of 0.93 indicating that Profound Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Predictive Oncology Positive
Profound Medical Very Positive

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profound Medical has higher revenue and earnings than Predictive Oncology. Profound Medical is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Predictive Oncology$120K641.09-$233.10M-$8.18N/A
Profound Medical$16.10M14.96-$42.57M-$1.24N/A

Profound Medical has a consensus price target of $12.00, suggesting a potential upside of 81.00%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts clearly believe Profound Medical is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Profound Medical
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Profound Medical beats Predictive Oncology on 12 of the 16 factors compared between the two stocks.

How does Predictive Oncology compare to Orchestra BioMed?

Predictive Oncology (NASDAQ:AGPU) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Predictive Oncology has a beta of 3.47, indicating that its stock price is 247% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Orchestra BioMed has higher revenue and earnings than Predictive Oncology. Orchestra BioMed is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Predictive Oncology$120K641.09-$233.10M-$8.18N/A
Orchestra BioMed$33.48M7.33-$52.70M-$0.97N/A

Orchestra BioMed has a consensus price target of $13.60, indicating a potential upside of 231.71%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Orchestra BioMed
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Orchestra BioMed has a net margin of -166.96% compared to Predictive Oncology's net margin of -470,383.31%. Orchestra BioMed's return on equity of -157.46% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Predictive Oncology-470,383.31% -7,363.67% -626.32%
Orchestra BioMed -166.96%-157.46%-60.18%

In the previous week, Predictive Oncology had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 2 mentions for Predictive Oncology and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.87 beat Predictive Oncology's score of 0.93 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company Overall Sentiment
Predictive Oncology Positive
Orchestra BioMed Very Positive

Summary

Orchestra BioMed beats Predictive Oncology on 12 of the 16 factors compared between the two stocks.

How does Predictive Oncology compare to TriSalus Life Sciences?

Predictive Oncology (NASDAQ:AGPU) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

TriSalus Life Sciences has a net margin of -60.85% compared to Predictive Oncology's net margin of -470,383.31%. TriSalus Life Sciences' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Predictive Oncology-470,383.31% -7,363.67% -626.32%
TriSalus Life Sciences -60.85%N/A -69.91%

In the previous week, TriSalus Life Sciences had 6 more articles in the media than Predictive Oncology. MarketBeat recorded 8 mentions for TriSalus Life Sciences and 2 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.93 beat TriSalus Life Sciences' score of 0.21 indicating that Predictive Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Predictive Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TriSalus Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

TriSalus Life Sciences has higher revenue and earnings than Predictive Oncology. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Predictive Oncology$120K641.09-$233.10M-$8.18N/A
TriSalus Life Sciences$45.15M5.13-$39.23M-$1.41N/A

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

TriSalus Life Sciences has a consensus price target of $7.50, suggesting a potential upside of 98.94%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Predictive Oncology has a beta of 3.47, suggesting that its share price is 247% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Summary

TriSalus Life Sciences beats Predictive Oncology on 11 of the 16 factors compared between the two stocks.

Get Predictive Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGPU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGPU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGPU vs. The Competition

Export
MetricPredictive OncologySurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ Exchange
Market Cap$76.93M$2.78B$4.29B$12.05B
Dividend YieldN/AN/A10.25%5.66%
P/E Ratio-0.8713.5222.2924.42
Price / Sales641.09334.04159.55123.88
Price / CashN/A8.0340.1937.92
Price / Book0.615.4726.926.82
Net Income-$233.10M$7.39M$116.61M$337.56M
7 Day Performance-2.87%-3.57%0.25%1.16%
1 Month Performance21.54%-2.76%0.25%3.16%
1 Year PerformanceN/A12.97%14.25%30.60%

Predictive Oncology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGPU
Predictive Oncology
0.7798 of 5 stars		$7.11
flat		N/AN/A$76.93M$120KN/A30
TMCI
Treace Medical Concepts
2.511 of 5 stars		$4.23
+13.4%		$4.77
+12.8%		-28.4%$274.40M$212.69MN/A250
SGHT
Sight Sciences
3.0799 of 5 stars		$4.82
-0.6%		$8.14
+69.0%		+24.2%$262.26M$77.36MN/A210
PROF
Profound Medical
1.8813 of 5 stars		$6.71
-1.6%		$12.00
+78.8%		+1.4%$243.84M$16.10MN/A150
OBIO
Orchestra BioMed
4.325 of 5 stars		$4.02
-0.2%		$13.60
+238.3%		+32.7%$240.72M$33.48MN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AGPU) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel